Takeda to sell 18 items of diabetes & OTC to Celltrion

The copyright of 18 items in the Asia-Pacific region was moved to Celltrion, amounting to ₩332.4 billion

The sale of some items of diabetes and OTC by Takeda was confirmed.

 

Celltrion is the company that acquires these items.

 

Recently, the headquarters of Takeda trademarks, for patents, trademarks, and rights to sell 18 non-core generic and OTC sold in nine countries, including Korea, Thailand, Taiwan, Hong Kong, Macau, Philippines, Singapore, Malaysia, and Australia, signed a contract to sell the rights to sales to Celltrion for ₩33.2 billion.

 

The acquisition is through a Singapore subsidiary.

 

The acquisition is through a Singapore subsidiary.

 

The 18 items sold include Nesina, Actos, Edarbi, and OTC such as Whitetuben and Albothyl.

 

The product group has generated sales of approximately $140 million as of 2018.

 

In the industry, rumors over the sale of Takeda's items and related primary care division (PCBU) and consumer healthcare division (OTCBU) were booming, but both divisions were included.

 

In accordance with the production and supply agreement between Takeda and Celltrion, Takeda will continue to take charge of producing assets for sale, and will supply it to Celltrion.

 

In the future, the technology transfer process will supply the main products acquired by Celltrion Pharmaceutical's cGMP (Current Good Manufacturing Practices) facility to domestic and overseas markets.

 

Under the terms of the agreement, Celltrion will take over the rights of the portfolio in the Asia-Pacific market through procedures such as the Fair Trade Commission.

 

Celltrion is expected to end its business acquisition in the fourth quarter of this year after approval by local authorities, such as a business combination report.

 

With this acquisition, Celltrion has secured the rights to patent, trademark, and sell 18 items in nine countries.

 

Celltrion Pharmaceuticals and Celltrion Healthcare, which have sales networks in Korea, Southeast Asia, and Australia, are in charge of sales.

 

This acquisition is also Celltrion's first major merger and acquisition (M&A).

 

Celltrion explained that the acquisition of the chronic disease treatment market is increasing in importance, and that the company has decided to acquire it as a step toward becoming a global comprehensive pharmaceutical bio company.

 

Celltrion said, "It is expected that Celltrion will strengthen its chemical product line with biopharmaceutical products that have maintained its global competitiveness, such as autoimmune disease treatments and anti-cancer drugs, and make it a leap forward to become a global pharmaceutical pharmaceutical company." Meanwhile, Takeda completed a deal in March to sell non-core assets in the Russia-CIS region to Stada for $660 million, and non-core assets in the Near East, Middle East and Africa were sold to Acino for $200 million.

 

In last July, it sold Xiidra to Novartis for approximately $5.3 billion.

 

Earlier this year, non-core assets in Latin America were $825 million for Hypera Pharma and in Europe, the sale was confirmed to the Orifarm Group for about $670 million, including two production bases located in Denmark and Poland.